{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:56:18Z","timestamp":1789826178366,"version":"4.0.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Current treatment for visceral leishmaniasis is based on drugs such as pentavalent antimony and amphotericin B. However, this treatment remains mostly ineffective and expensive, resulting in several side effects and generating resistance. Apigenin, a flavonoid present in fruits and vegetables, has demonstrated several biological functions. In the present study, we observed a concentration-dependent inhibition of the <jats:italic>L. infantum<\/jats:italic> promastigote in the presence of apigenin, exhibiting an IC<jats:sub>50<\/jats:sub> value of 29.9 \u00b5M. Its effect was also evaluated in <jats:italic>L. infantum<\/jats:italic>-infected murine peritoneal macrophages, presenting an C<jats:sub>50<\/jats:sub> value against intracellular amastigotes of 2.3 \u00b5M and a selectivity index of 34.3. In a murine model of visceral leishmaniasis, the <jats:italic>in vivo<\/jats:italic> effect of apigenin was measured using short-term and long-term treatment schemes. Treatment with apigenin demonstrated 99.7% and 94% reductions in the liver parasite load in the short-term and long-term treatment schemes, respectively. Furthermore, no alterations in serological and hematological parameters were observed. Taken together, these results suggest that apigenin is a potential candidate for visceral leishmaniasis chemotherapy by oral administration.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1066407","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T04:48:19Z","timestamp":1680670099000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Apigenin is a promising molecule for treatment of visceral leishmaniasis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yago S. S.","family":"Emiliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmo E.","family":"Almeida-Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: The second 10 years","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1128\/AAC.01787-15","article-title":"Preclinical studies evaluating subacute toxicity and therapeutic efficacy of LQB-118 in experimental visceral leishmaniasis","volume":"60","author":"Cunha-Junior","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","article-title":"DNDi 2021 annual report - unlocking the promise of medical innovation for all","volume-title":"Anual report","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1021\/acs.jnatprod.8b00356","article-title":"Efficacy of apigenin and miltefosine combination therapy against experimental cutaneous leishmaniasis","volume":"81","author":"Emiliano","year":"2018","journal-title":"J. Nat. Prod."},{"key":"B5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1021\/acs.jnatprod.5b00011","article-title":"Effect of apigenin on leishmania amazonensis is associated with reactive oxygen species production followed by mitochondrial dysfunction","volume":"78","author":"Fonseca-Silva","year":"2015","journal-title":"J. Nat. Prod."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e14666","DOI":"10.1371\/journal.pone.0014666","article-title":"Reactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in leishmania amazonensis","volume":"6","author":"Fonseca-Silva","year":"2011","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1021\/np400193m","article-title":"Reactive oxygen species production by quercetin causes the death of leishmania amazonensis intracellular amastigotes","volume":"76","author":"Fonseca-Silva","year":"2013","journal-title":"J. Nat. Prod."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0004442","DOI":"10.1371\/journal.pntd.0004442","article-title":"Oral efficacy of apigenin against cutaneous leishmaniasis: Involvement of reactive oxygen species and autophagy as a mechanism of action","volume":"10","author":"Fonseca-Silva","year":"2016","journal-title":"PloS Negl. Trop. Dis."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.579891","article-title":"Use of natural products in leishmaniasis chemotherapy: An overview","volume":"8","author":"Gervazoni","year":"2020","journal-title":"Front. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0006930","DOI":"10.1371\/journal.pntd.0006930","article-title":"2\u2019-hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant leishmania amazonensis","volume":"12","author":"Gervazoni","year":"2018","journal-title":"PloS Negl. Trop. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1021\/np400624d","article-title":"In vitro and in vivo effects of (-)-epigallocatechin 3-o-gallate on leishmania amazonensis","volume":"76","author":"Inacio","year":"2013","journal-title":"J. Nat. Prod."},{"key":"B12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.exppara.2012.06.008","article-title":"Mitochondrial damage contribute to epigallocatechin-3-gallate induced death in leishmania amazonensis","volume":"132","author":"Inacio","year":"2012","journal-title":"Exp. Parasitol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1021\/acs.jnatprod.9b00632","article-title":"(-)-Epigallocatechin 3-O-Gallate as a new approach for the treatment of visceral leishmaniasis","volume":"82","author":"Inacio","year":"2019","journal-title":"J. Nat. Prod."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e3093","DOI":"10.1371\/journal.pntd.0003093","article-title":"The effect of (-)-epigallocatechin 3-O\u2013gallate in vitro and in vivo in leishmania braziliensis: Involvement of reactive oxygen species as a mechanism of action","volume":"8","author":"Inacio","year":"2014","journal-title":"PloS Negl. Trop. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.42.3.654","article-title":"Short- and long-term efficacy of hexadecylphosphocholine against established leishmania infantum infection in BALB\/c mice","volume":"42","author":"Le Fichoux","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1574-6968.2006.00263.x","article-title":"Antiparasitic activity of flavonoids and isoflavones against cryptosporidium parvum and encephalitozoon intestinalis","volume":"259","author":"Mead","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.3390\/ijms14023395","article-title":"Natural products as a source for treating neglected parasitic diseases","volume":"14","author":"Ndjonka","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B19","volume-title":"Leishmaniasis: Epidemiological report in the americas","year":"2018"},{"key":"B20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd1824","article-title":"Opportunities and challenges in antiparasitic drug discovery","volume":"4","author":"Pink","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B22","article-title":"Global leishmaniasis surveillance: 2019\u20132020, a baseline for the 2030 roadmap","volume-title":"Weekly epidemiological record","author":"Ruiz-Postigo","year":"2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20061305","article-title":"The therapeutic potential of apigenin","volume":"20","author":"Salehi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1128\/AAC.50.4.1352-1364.2006","article-title":"Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: In vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies","volume":"50","author":"Tasdemir","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of leishmaniasis: Present challenges","volume":"145","author":"Uliana","year":"2017","journal-title":"Parasitology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"van Griensven","year":"2012","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.drudis.2017.06.004","article-title":"Leishmaniasis drug discovery: Recent progress and challenges in assay development","volume":"22","author":"Zulfiqar","year":"2017","journal-title":"Drug Discov. Today"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1066407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T04:48:22Z","timestamp":1680670102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1066407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":27,"alternative-id":["10.3389\/fcimb.2023.1066407"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1066407","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"article-number":"1066407"}}